Subject(s)
COVID-19 Vaccines , COVID-19 , COVID-19/prevention & control , Humans , Immunity, Cellular , Immunosuppression Therapy , RNA, Messenger , VaccinationABSTRACT
Telogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies, and febrile states. We report three cases of TE occurred after severe Sars-Cov-2 infection and provide our clinical management, according to Sars-Cov-2 hygiene measures. Only one case report has been found in the literature associating anagen effluvium during severe Sars-Cov-2 infection. Other studies reported the exacerbation of a preexisting TE, correlated to the stress of lockdown. In our cases, patients never had a TE diagnosis before and did not report previous evident hair loss. TE can be associated with post severe Sars-Cov-2 infection. From our revision of the literature, this is the first case-series describing TE in post severe Sars-Cov-2 patients. Further studies are needed to evaluate the relationship between TE and Sars-Cov-2 infection.
Subject(s)
Alopecia Areata , Alopecia , COVID-19 , Aged , Alopecia/diagnosis , Alopecia/etiology , COVID-19/complications , Communicable Disease Control , Female , Humans , Middle Aged , SARS-CoV-2ABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects approximately 20% of children and 10% of adults. The implication of vaccines as a trigger for the de novo onset of AD in children or as a cause of exacerbation in individuals with a history of AD has long been debated. We present a brief review of the literature on AD and traditional vaccinations, proposing in addition the main recommendations for the management of patients with AD undergoing the vaccine against the SARS-COV-2 virus. Live attenuated vaccines seem to be associated with a relapse of AD and/or complications, such as eczema vaccinatum. For non-live vaccines, no adverse events are noted in atopic subjects. Since the Covid-19 vaccine is mRNA or viral vectored vaccine and there are no other currently used vaccines of this type, the same recommendations are applied as for all other non-live vaccines.
Subject(s)
COVID-19 , Dermatitis, Atopic , Adult , COVID-19 Vaccines , Child , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/therapy , Dermatologists , Humans , Pandemics , SARS-CoV-2 , VaccinationABSTRACT
Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Italy has been the first nation affected by the coronavirus pandemic and is the second in the number of reported deaths in the European Union. In the United Hospital of Ancona, a specialist outpatient clinic dealing with diagnosis and treatment of immunomediated skin diseases has been operating since 1985, and 291 patients with hidradenitis suppurativa (HS) are currently being treated. Several cutaneous immunomediated diseases, including HS, are treated with biologic and nonbiologic immunosuppressive and immunomodulatory drugs. Since the end of February 2020, when the SARS-CoV-2 pandemic had already spread in most of Italy, a task force comprised of seven specialists has been set up with the aim of addressing problems relating to the specific risk for this class of patients in relation to SARS-CoV-2 infection and immunosuppressive ongoing therapy. In this article, the management of HS disease during the COVID-19 pandemic is discussed. The main goal was to evaluate the risk/benefit in modulating treatment taking into consideration patients' risk of exposure to SARS-CoV-2 virus.
Subject(s)
Biological Products/therapeutic use , COVID-19/immunology , Hidradenitis Suppurativa/drug therapy , Immunologic Factors/therapeutic use , SARS-CoV-2/immunology , Adult , Biological Products/adverse effects , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/virology , Comorbidity , Female , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/epidemiology , Hidradenitis Suppurativa/immunology , Host-Pathogen Interactions , Humans , Immunocompromised Host , Immunologic Factors/adverse effects , Male , Middle Aged , Patient Safety , Risk Assessment , Risk Factors , SARS-CoV-2/pathogenicity , Treatment Outcome , Young AdultABSTRACT
Two months have passed since the World Health Organization (WHO) declared the pandemic of the Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV-2 virus, on 11 March 2020. Medical and healthcare workers have continued to be on the frontline to defeat this disease, however, continual changes are being made to their working habits which are proving to be difficult. Although the skin is not the main target of the SARS-CoV-2 infection, it is strongly involved both directly and indirectly, in many aspects of dermatological disease management, and particularly in pediatric dermatology. In this manuscript, our goal was to provide a "up-to-date" account on this topic, through analysis of current literature and sharing our experiences during this pandemic.